阿柏西普在增殖型糖尿病视网膜病变患者中的应用效果

Application effect of aflibercept in patients with proliferative diabetic retinopathy

目的 分析阿柏西普在增殖型糖尿病视网膜病变(PDR)患者中的应用效果。方法 选取2019年7月至2021年7月我院收治的80例PDR患者为研究对象,将其随机分为对照组(n=40,玻璃体切除术治疗)和研究组(n=40,阿柏西普+玻璃体切除术治疗)。比较两组的治疗效果。结果 研究组的治疗总有效率为95.00%,高于对照组的77.50%(P<0.05)。治疗后,研究组的收缩期血流峰值流速(PSV)、舒张末期血流速度(EDV)高于对照组,阻力指数(RI)及血管内皮生长因子(VEGF)、促红细胞生成素(EPO)、血管生成素-2(Ang-2)、缺氧诱导因子-1α(HIF-1α)、miR-210水平低于对照组(P<0.05)。术后1周、1个月、3个月,研究组的最佳矫正视力高于对照组(P<0.05)。结论 阿柏西普+玻璃体切除术治疗PDR患者可取得理想疗效,能改善血流动力学、血清指标及提高术后视力,值得临床推广及应用。

Objective To analyze the application effect of aflibercept in patients with proliferative diabetic retinopathy(PDR).Methods A total of 80 patients with PDR admitted in our hospital from July 2019 to July 2021 were selected as the objects and randomly divided into control group(n=40,treated with vitrectomy)and study group(n=40,treated with aflibercept+vitrectomy).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was 95.00%,which was higher than 77.50%in the control group(P<0.05).After treatment,the peak systolic velocity(PSV)and end diastolic velocity(EDV)in the study group were higher than those in the control group,and the resistance index(RI)and the levels of vascular endothelial growth factor(VEGF),erythropoietin(EPO),angiopoietin-2(Ang-2),hypoxia inducible factor-1α(HIF-1α)and miR-210 were lower than those in the control group(P<0.05).At 1 week,1 month and 3 months after operation,the best corrected visual acuity of the study group was higher than that of the control group(P<0.05).Conclusion The aflibercept+vitrectomy can achive ideal results in the treatment of PDR patients,improve hemodynamics,serum indicators and enhance postoperative visual acuity.It is worthy of clinical promotion and application.